MX2016011219A - Procedimiento para fabricar un producto de acetato de glatiramer. - Google Patents
Procedimiento para fabricar un producto de acetato de glatiramer.Info
- Publication number
- MX2016011219A MX2016011219A MX2016011219A MX2016011219A MX2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A
- Authority
- MX
- Mexico
- Prior art keywords
- glatiramer acetate
- mannitol
- aqueous pharmaceutical
- pharmaceutical solution
- suitable container
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 5
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 4
- 229930195725 Mannitol Natural products 0.000 abstract 4
- 235000010355 mannitol Nutrition 0.000 abstract 4
- 239000000594 mannitol Substances 0.000 abstract 4
- 239000003186 pharmaceutical solution Substances 0.000 abstract 4
- 239000000706 filtrate Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 1
- 229940071643 prefilled syringe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La patente proporciona un proceso de preparación de una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de: (i) obtener una solución farmacéutica acuosa de acetato de glatiramer y manitol; (ii) filtrar la solución farmacéutica acuosa a una temperatura de por encima de 0 °C hasta 17.5 °C para producir un filtrado; y (iii) llenar el contenedor adecuado con el filtrado obtenido después de realizar la etapa (ii), a fin de preparar de este modo la preparación farmacéutica de acetato de glatiramer y manitol en el contenedor adecuado. Esta patente proporciona, además, una solución farmacéutica acuosa que comprende 40 mg/ml de acetato de glatiramer y 40 mg/ml de manitol, en donde la solución farmacéutica acuosa a) tiene una viscosidad en el intervalo de 2.0 a 3.5 cPa; o b) tiene una osmolalidad en el intervalo de 275 a 325 mosmol/Kg. Esta patente también proporciona una jeringa precargada, un inyector automático y un método de tratamiento de un paciente humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
| PCT/US2015/051203 WO2016122722A1 (en) | 2015-01-28 | 2015-09-21 | Process for manufacturing glatiramer acetate product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011219A true MX2016011219A (es) | 2016-11-30 |
| MX352734B MX352734B (es) | 2017-12-06 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011219A MX352734B (es) | 2015-01-28 | 2015-09-21 | Procedimiento para fabricar un producto de acetato de glatiramer. |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (es) |
| EP (3) | EP3113785A4 (es) |
| JP (2) | JP2018503627A (es) |
| KR (2) | KR101737295B1 (es) |
| CN (1) | CN107530394B (es) |
| AR (1) | AR102096A1 (es) |
| AU (4) | AU2015380381B2 (es) |
| BR (1) | BR112016023736A2 (es) |
| CA (2) | CA2965890A1 (es) |
| CL (1) | CL2016002607A1 (es) |
| CY (1) | CY1118826T1 (es) |
| DK (1) | DK3050556T3 (es) |
| EA (3) | EA028484B1 (es) |
| ES (1) | ES2584190T3 (es) |
| HK (1) | HK1225309B (es) |
| HR (1) | HRP20170625T1 (es) |
| HU (1) | HUE034059T2 (es) |
| IL (3) | IL247851A0 (es) |
| LT (1) | LT3050556T (es) |
| ME (1) | ME02721B (es) |
| MX (1) | MX352734B (es) |
| PE (1) | PE20170296A1 (es) |
| PL (1) | PL3050556T3 (es) |
| PT (1) | PT3050556T (es) |
| RS (1) | RS55959B1 (es) |
| RU (1) | RU2669769C2 (es) |
| SI (1) | SI3050556T1 (es) |
| UA (1) | UA116060C2 (es) |
| WO (1) | WO2016122722A1 (es) |
| ZA (1) | ZA201606903B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| DE69427226T2 (de) | 1993-03-24 | 2001-08-30 | Owen Mumford Ltd | Vorrichtung zur injektion |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DE69940888D1 (de) | 1998-09-25 | 2009-06-25 | Yeda Res & Dev | Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| WO2000027417A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| AU2001238469C1 (en) | 2000-02-18 | 2006-08-24 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU7528001A (en) | 2000-06-05 | 2001-12-17 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| SI1459065T1 (sl) | 2001-12-04 | 2010-11-30 | Teva Pharma | Postopki za merjenje potentnosti glatiramer acetata |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| WO2004064717A2 (en) | 2003-01-21 | 2004-08-05 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
| US20070037740A1 (en) | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| EP1638589B1 (en) | 2003-05-14 | 2014-03-26 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| JP2007531701A (ja) | 2003-07-18 | 2007-11-08 | バクスター・インターナショナル・インコーポレイテッド | 制御された相分離により調製される小球状粒子の作製方法、使用および組成物 |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| WO2005063800A2 (en) | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| WO2005084377A2 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| DE602005018800D1 (de) | 2004-09-09 | 2010-02-25 | Teva Pharma | Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure |
| EP1797109B1 (en) | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| JP5297653B2 (ja) | 2004-10-29 | 2013-09-25 | サンド・アクチエンゲゼルシヤフト | グラチラマーの製造法 |
| UA93669C2 (ru) | 2005-02-02 | 2011-03-10 | Тева Фармасьютикл Индастриз, Лтд. | Способ приготовления полипептидной смеси c использованием гидрогенолиза |
| RS52867B (en) | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| JP2009542864A (ja) | 2006-07-05 | 2009-12-03 | モメンタ ファーマシューティカルズ インコーポレイテッド | コポリマー１の調製のための改良法 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| EP2381254B2 (en) | 2007-06-21 | 2017-07-19 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| JP2011504925A (ja) | 2007-11-28 | 2011-02-17 | テバ ファーマシューティカル インダストリーズ リミティド | 臨床的に確実な多発性硬化症の発症を遅延させる方法 |
| CN102026623B (zh) | 2008-05-14 | 2013-08-14 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| DK2275086T3 (da) * | 2009-07-15 | 2012-07-09 | Teva Pharma | Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf |
| EP2405749B1 (en) | 2009-08-20 | 2013-05-08 | Yeda Research and Development Co., Ltd. | Low frequency glatiramer acetate therapy |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| US9029507B2 (en) | 2011-02-14 | 2015-05-12 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| US10793307B2 (en) * | 2012-07-06 | 2020-10-06 | 3-D Matrix, Ltd. | Fill-finish process for peptide solutions |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| EP2941274A4 (en) | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CA2903127A1 (en) | 2013-03-12 | 2014-10-09 | Teva Pharmaceutical Industries Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active IP Right Grant
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active IP Right Grant
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en active Application Filing
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en active Active
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es unknown
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-01 HK HK16113726A patent/HK1225309B/zh unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116060C2 (uk) | Спосіб одержання продукту на основі глатирамеру ацетату | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| WO2015095624A3 (en) | Drug mixing and delivery system and method | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| EA201690207A1 (ru) | Композиция традиционной китайской медицины и препарат из нее и их применение | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| SA517390475B1 (ar) | نظام أكياس متعددة وطريقة لتحضير مكونات الدم | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| MX2017008330A (es) | Productos para el suministro de compuestos de diagnóstico/terapeuticos al corazon. | |
| MX2017015664A (es) | Administracion intravenosa de citrulina durante cirugia. | |
| PH12017501828A1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. | |
| PL2996675T3 (pl) | Formulacja farmaceutyczna, sposób wytwarzania formulacji farmaceutycznej i roztwór do infuzji oraz ich zastosowanie jako wyrobu medycznego i/lub leku | |
| WO2014075119A3 (de) | Vorrichtung und verfahren zur herstellung, dosierung und verpackung von arzneimitteln | |
| MX2016002091A (es) | Extracto de la planta rumex hymenosepalus con actividad hiperglucemiante. | |
| Bianchi | DRESS syndrome: case report | |
| EA201500385A1 (ru) | Способ получения интерферона бета 1-альфа и фармацевтическая композиция, содержащая интерферон бета 1-альфа | |
| IN2014MU01178A (es) | ||
| TH155343A (th) | องค์ประกอบเชิงเภสัชกรรมของเบนโซไดอะซีพีน (benzodiazepine) แบบใช้ทางในจมูก | |
| EA201400452A1 (ru) | Способ получения противоопухолевого препарата на основе доцетаксела | |
| AR100128A1 (es) | Método de elaboración de gel con hormona liberadora de gonadotropina (gnrh) | |
| TH162713A (th) | ยาชนิดรวมที่ประกอบรวมด้วยเจมิกลิปทินและเมตฟอร์มินและวิธีการสำหรับ การเตรียมยาชนิดรวมดังกล่าว |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |